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Ketogenic diet therapies (KDTs) have been used to treat epilepsy for nearly 100 years. Although 
effective, restrictive diet patterns and unknown impacts on long-term health outcomes often 
prevent their use as first-line therapy. To date, a distinct mechanism of action for KDTs has not 
been determined and evidence suggests fatty acids (FAs) may play a role in eliciting anti-seizure 
effects. This dissertation aimed to provide insights into the effect of polyunsaturated fatty acids 
(PUFAs) and saturated fatty acids (SFAs) on seizure presence and severity through the analysis of 
dietary intake in a cohort of patients admitted to an epilepsy monitoring unit at Nebraska 
Medicine. Seizure activity was monitored throughout the inpatient stay via continuous video 
electrocephalogram monitoring (EEG) and dietary intake was determined by administering a food 
frequency questionnaire. PUFAs were evaluated separately while SFAs were analyzed by carbon 
length groupings: short chain (SCFA), medium chain (MCFA) and long chain (LCFA). EEG 
reports were reviewed and assessed for seizure presence (yes/no) and seizure severity (score of 1-
4). Differences in median FA intakes across seizure presence and severity groups were evaluated 
and regression models assessed the ability of PUFAs and SFAs to act as predictors of seizure 
presence and severity, respectively. Seizure presence was observed in 31 of 82 (37.8%) subjects 
included in the final analysis. While no statistically significant (p <0.05) differences of PUFA or 
SFA intake were observed across seizure presence or severity groups, clinical observations 
suggest the relationship between FA intake and seizure severity. Even with dietary intakes far 
below what may be considered a therapeutic dose, the influence of FA intake appeared possible in 
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subjects with seizure presence. Furthermore, a trend toward significance was seen in the 
multivariate linear regression model with increased MCFA intake having an inverse linear 
relationship with severity scores (β = -0.11, p = 0.16). Results from this dissertation suggest 
specific dietary FAs have potential anti-seizure properties that warrant exploration as epilepsy 
treatment. A minimally invasive, targeted dietary treatment could decrease the devastating side 
effects of epilepsy, reduce the staggering cost of treatment and improve quality of life for patients 
and their families.   
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Epilepsy is a devastating condition that impacts 3.4 million people worldwide with 150,000 
new cases of epilepsy per year. In 2013, annual direct cost estimates ranged from $10,000 to a 
staggering $47,000 per year [1]. The multifaceted impact of the condition on those affected is 
extensive. Not only is seizure occurrence unpredictable and potentially fatal, but may also result 
in cognitive impairment, social exclusion, psychiatric comorbidities and a decreased quality of 
life [2]. According to the Epilepsy Foundation, the official definition of a seizure is “a transient 
occurrence of signs and/or symptoms due to an abnormal or excessive synchronous neuronal 
activity in the brain.” Epilepsy is characterized by abnormal brain activity thought to be due to 
factors including genetics, developmental disorders or neurologic damage such as a traumatic 
brain injury, hypoxia or fevers [3]. These factors, in turn, may lead to hyperexcitability and 
seizure activity by negatively impacting neurotransmitters, ion channels, neuroinflammation, 
oxidative stress or the microbiome.  
Seizures are classified by where they originated in the brain. Determining location of onset is 
important because it effects treatment. In 2017, the International League Against Epilepsy (ILAE) 
revised its classification of seizures to make diagnoses accurate. The organization divided 
seizures into two broad groups: focal and generalized. Focal (previously described as partial) 
seizures start in an area or network of cells on one side of the brain, while generalized seizures 
involve networks on both sides of the brain at onset. Seizures are then sub-categorized by 
describing awareness and motor onset (Table 1). If awareness remains intact, even if the person 
were unable to talk or respond during a seizure, the seizure would be classified a focal aware 
seizure. Focal impaired awareness (previously described as complex partial) seizures can make a 
person confused or dazed and are unable to respond to questions or direction for up to a few 





Table 1: ILAE Seizure Classifications with Possible Motor and Non-Motor Characteristics 





Motor Non-Motor Motor Non-Motor 
Automatisms Autonomic Tonic-clonic Typical 
Atonic Behavioral arrest Clonic Atypical 
Clonic Cognitive Tonic Myoclonic 
Epileptic Spasms Emotional Myoclonic Eyelid myoclonia 
Hyperkinetic Sensory Myoclonic-tonic-clonic  
Myoclonic  Myoclonic-atonic  
Tonic  Atonic  
  Epileptic Spasms  
    
Previously accepted seizure classification nomenclature noted in parentheses 
ILAE: International League Against Epilepsy  
 
 
Current drug treatments target seizure symptoms and do not directly affect or prevent the 
underlying cause contributing to the epileptic state or epileptogenesis [4-7]. Epileptogenesis is a 
continuous and chronic process by which a brain network, that was previously normal, is 
functionally altered toward increased seizure susceptibility, thus having an enhanced probability 
to generate spontaneous recurrent seizures [8]. Although treatments may improve seizure 
symptoms and provide a better quality of life, the underlying cause of the seizure needs to be 
identified in order to inhibit epileptogenesis and prevent brain insult, microglial cell activation 
and neuronal cell death.  
Up to 65% of individuals with epilepsy will have seizures controlled with anti-seizure 
medications (ASMs) or enter spontaneous remission in their lifetime [9]. However, this leaves a 
large percentage of patients that are refractory to drug therapy. Some of the current methods for 
treating refractory epilepsy include surgery or vagus nerve stimulation. Nutritional approaches to 






The term ketogenic diet therapy (KDT) refers to any diet therapy in which dietary 
composition results in a ketogenic state of human metabolism [10]. Since the 1930s, 
observational trials, randomized controlled trials (RCTs) and meta-analyses have consistently 
shown KDTs are able to significantly reduce seizure frequency in children and adolescents with 
refractory epilepsy [11-16]. The diet generally refers to a high fat, low carbohydrate and moderate 
protein diet. Macronutrient distribution is described by a ketogenic diet (KD) ratio, or the ratio of 
fat to carbohydrate and protein. KDTs imitate the biochemical effects of fasting and induces a 
shift away from glycolic energy production toward energy generation through oxidative 
phosphorylation, leading to fatty acid β-oxidation and ketone production [17]. Beta-
hydroxybutyrate (BHB) is the predominate ketone measured in plasma or urine and has been used 
as a clinical measure of KD implementation, effectiveness and adherence. 
Currently, there are four major KDTs (Table 2): the classic ketogenic diet (cKD), the medium 
chain triglyceride ketogenic diet (MCTKD), the modified Atkins diet (MAD), and the low 
glycemic index treatment (LGIT) [18].  
First proposed by Wilder et al. in 1921, the cKD is considered the most restrictive of the 
described KDTs. Food is weighed on a gram scale and urine ketone bodies (KBs) are measured to 
ensure the patient remains in ketosis. The cKD is generally based upon consumption of a 3:1 to 
4:1 KD ratio and is often characterized by high intakes of long chain fatty acids from butter and 
cream [17, 19]. Following the development of the cKD, new diets have been developed in an 
attempt to increase retention and palatability while mimicking the effects produced by the 







Table 2: KDT Diet Patterns and Macronutrient Distributions 
KDT Diet Pattern 
Percent Total Daily Energy Intake 
Fat Carbohydrate Protein 
cKD KD Ratio of 3:1–4:1 90 4 6 
Traditional MCTKD 60% total energy intake from MCT 70–75 15–18 10 
Modified MCTKD 30% total energy intake from MCT 70–75 15–18 10 
MAD KD ratio of 1:1–2:1 60–65 5–10 30 
LGIT 
40–60 g carbohydrate per day  
Restricts carbohydrate sources to a GI < 50 
60 10 30 
KDT: Ketogenic Diet or Ketogenic Diet Therapy; cKD: classic ketogenic diet; MAD: Modified Atkins diet; MCTKD: 
medium chain triglyceride ketogenic diet; LGIT: low glycemic index treamtent  
 
The MCTKD was developed in 1971 and encourages medium chain triglycerides (MCTs) as 
a large percentage of daily fat intake [18, 20]. Historically, the traditional MCTKD provided 60% 
of total energy from MCTs. However, due to the tendency of MCTs to cause gastrointestinal side 
effects, a modified MCTKD, which recommends 30% of total energy intake from MCTs, was 
developed. Fats are often introduced into the diet via an oral supplement that contains only 
MCTs. The medium-chain saturated fatty acid (MCFA) octanic acid (C8:0) is the most abundant 
FA in the diet (50-75% content), followed by the 10-carbon decanoic acid (23-45% content) with 
minimal 12-carbon lauric acids (1-5%) [21]. After ingestion, MCFAs are carried directly from the 
digestive system to the liver for KB production via the portal vein [11]. After crossing the blood 
brain barrier (BBB), KBs are oxidized by the brain to provide a direct fuel source [22]. With an 
increased ketogenic potential, less total fat is needed in the MCTKD, which allows for increased 
carbohydrate and protein intake, likely resulting in more food choices.  
Later, the MAD and LGIT were proposed as alternatives to the cKD and MCTKD. The 
MAD, created at Johns Hopkins Hospital in 2003, is considered a less restrictive alternative to the 
cKD with a KD ratio of 1:1 to 2:1 and an unrestricted calorie intake [23]. Upon implementation, 
carbohydrates are limited to 10 grams (gms) per day in children and are increased after one month 
to 15 gms with a final increase to 20 to 30 gms per day depending on seizure severity. Finally, 
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The LGIT, initially introduced in 2005, allows 40 to 60 gms carbohydrate per day but restricts 
sources of carbohydrates to a glycemic index (GI) of less than 50 to prevent postprandial 
increases in blood glucose [24]. Foods with a high GI produce substantial increases in blood 
glucose and insulin, whereas those with a low GI (e.g. vegetables and unprocessed whole grains) 
induce lower postprandial plasma glucose and insulin profiles [25]. Fats and proteins are 
unrestricted. With liberalized KD ratios and lack of MCT supplementation, the MAD and LGIT 
do not produce the amount of ketones seen in the cKD or MCTKD. However, both have proven 
to be effective in the treatment of epilepsy against the more restrictive diets [13, 26, 27]. 
Although KDTs have proven to be effective, they are generally not considered a first-line 
treatment due to adverse effects of therapy and retention. In a systematic review of KDT 
prospective studies, more than 40 categories of adverse effects were identified [28]. These 
included direct negative effects on gastrointestinal function, lipid profiles, bones and ultimately 
growth. Adverse effects likely also have an enormous impact on retention rate of KDTs, which 
have been reported at years one and two to be 45.7% and 29.2%, respectively. Furthermore, 
attrition is also largely affected by poor educational and support systems in place for patients and 
families. Therefore, the ability to identify a mechanism of action which may be targeted through 
precision nutrition may be paramount in a novel line of treatment for individuals with epilepsy.  
After 100 years of use, the exact mechanism of KDTs remains unknown and no KDT has 
clearly shown superiority in an RCT of patients over the age of two [29]. Previous assumptions 
related the effectiveness of a KDT to the amount of BHB produced and measured. However, 
although significant elevations of BHB are seen during KDT, there are currently no significant 
correlations between levels and seizure activity [30]. In fact, the evolution from the most 
restrictive KDT, the cKD with a 4:1 KD ratio, to more liberal MAD and LGIT options with 
increased carbohydrate and protein provision, did not appear to impact efficacy. Therefore, a 
question of whether presence of BHB or ketone metabolism is strictly necessary for the clinical 
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effectiveness of KDTs is raised. Many hypothesize the KDT mechanism of action includes 
halting or reversing one or more of the hallmark consequences of seizures including 
neuroinflammation, oxidative stress or dysregulation of neurotransmitters and ion channels. [3].  
KDT was first developed to mimic the effects of starvation. When carbohydrates are present 
in human metabolism, glucose is metabolized to produce adenosine triphosphate (ATP) while 
fatty acids (FAs) are stored in the form of triglycerides. However, when intake is limited, 
triglycerides are β-oxidized and used to produce energy. As all KDTs provide greater than 50% 
of total daily energy intake from fat, the drastic elevation from the recognized norm would also 
lead to higher fat metabolism and β-oxidation (Figure 1). Therefore, another possibility, besides 
ketones directly inhibiting seizures, is that a very high fat diet elicits anti-seizure characteristics 
through the accumulation and metabolism of FAs [31, 32].  
 
 
FAs are carboxylic acids with a long aliphatic chain that is either saturated, monounsaturated 
or polyunsaturated. These nutrients are unique in the fact that they provide energy but are also 
metabolic regulators [33]. In the body, metabolism of fatty acids results in oxidation for energy, 
storage as triglycerides and use for phospholipid synthesis that form the structures of cell 
 
Figure 1: Increased FA Accumulation and Metabolism from Fasting States and 
KDTs. Lipolysis during a fasting states and increased FA consumption during 











membranes [34]. Interestingly, the human brain mobilizes FAs for oxidation, irrespective of diet 
or metabolic state and astrocytes and neural stem cells express all the enzymes necessary for fatty 
acid oxidation (FAO) [35-37].  Statistically significant elevations in serum polyunsaturated fatty 
acid (PUFA) and saturated fatty acid (SFA) concentrations have been recognized in animal and 
human subjects on KDT, likely due to the aforementioned increase in FAO [17, 38-43].  
Research suggests that modification of FA intake, under KDT or with a modified intake, can 
provide neuroprotection, reduce seizure frequency and increase seizure thresholds in pre-clinical, 
clinical and epidemiologic reports [44-48]. However, a gap in knowledge exists regarding the 





CHAPTER 1: REVIEW OF THE LITERATURE 
Polyunsaturated Fatty Acids (PUFAs) 
PUFAs are long-chain fat molecules that have more than one unsaturated carbon bond. 
According to the position of the carbon atom linked by the first unsaturated double bond in the 
methyl end of the carbon chain, PUFAs are divided into two major classes: omega (n)-3 and n-6 
FAs (Figure 2). Both are important cell-membrane components, essential for optimal brain 
function and potent mediators of inflammation [49]. Humans are unable to synthesize these long 
chain fatty acids and are required in the diet to prevent clinical deficiency.  
Adequate Intakes (AIs) are set at 
levels assumed to ensure nutritional 
adequacy when there is insufficient 
evidence to develop a Recommended 
Dietary Allowance (RDA). In 2002, 
the United States Institute of Medicine 
(IOM) established AIs for n-3 and n-6 
FAs (Table 3) [50]. Recommendations for n-3 and n-6 apply only to alpha-linolenic acid (ALA), 
and linoleic acid (LA), respectively. According to data from the 2011-2012 National Health and 
Nutrition Examination Survey, most children and adults in the United States consume 
recommended amounts of n-3s as ALA. 
ALA, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) are the primary n-3 
FAs. ALA (18:3) is present in plant oils such as flaxseed, soybean and canola oils and can be 
converted to EPA and DHA in the liver [51, 52]. However, with a very low conversion rate of 0-
4%, ingesting EPA and DHA directly from foods is the best way to increase levels in the body 
[53]. EPA (20:5) and DHA (22:6) are found in fish but originate in marine algae and 
phytoplankton. When fish consume phytoplankton that consumes algae, these n-3s accumulate in 
 
Figure 2: Chemical Structure of Polyunsaturated Fatty Acids 




their tissues [54]. Proposed dietary reference intakes (DRIs) for combined EPA and DHA are 
250-500 mg per day in healthy individuals [55]. N-3 FAs have long been recognized for their 
anti-inflammatory effects, but mechanisms underlying various protective effects are incompletely 
understood [56]. Interestingly, n-3 FAs have recently been found to serve as substrates for the 
biosynthesis of specialized pro-resolving lipid mediators (SPM) that promote the endogenous 
resolution of inflammation [57, 58]. SPM derived from the n-3 FAs DHA and EPA include the 
resolvin D (RvD)-, maresin (MaR)-, and protectin- series SPM, and the resolvin E (RvE)- series 
SPM, respectively [59]. Preclinical investigations indicate that these SPM are key in the active 
regulation of inflammation resolution [57, 58, 60-63]. 
 
Table 3: Adequate Intakes (AIs) for n-3 as ALA and n-6 as LA as proposed by the 
IOM [50] 
 ALA (gm/d) LA (gm/d) 
Age Male Female Male Female 
Birth to 6 months 0.5 0.5 4.4 4.4 
7-12 months 0.5 0.5 4.6 4.6 
1-3 years 0.7 0.7 7 7  
4-8 years 0.9 0.9 10 10 
9 -13 years 1.2 1.0 12 10 
14-18 years 1.6 1.1 16 11 
19-50 years 1.6 1.1 17 12 
51+ years 1.6 1.1 14 11 
AIs: Adequate Intakes; n-3: Omega 3; ALA: Alpha-Linolenic Acid; LA: Linoleic Acid 
 
Major forms of n-6 FAs include LA (18:2) and arachidonic acid (AA) (C20:4). LA is derived 
from vegetable and meat sources while AA is metabolized from LA. N-6 FAs have beneficial 
effects such as lowering LDL cholesterol, increasing HDL cholesterol and improving the body’s 
sensitivity to insulin. However, consuming large amounts of n-6 FAs increases the plasma 
concentrations of eicosanoids derived from AA metabolism. In contrast to n-3 FAs, AA generally 
exerts pro-inflammatory properties via its conversion by the cyclooxygenase (COX) and 
lipoxygenase (LOX) pathways to bioactive mediators called  eicosanoids (i.e. prostaglandins, 
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thromboxanes and leukotrienes) [64]. Yet, during the acute phase of an inflammatory response, 
AA metabolism can also change to the production of other eicosanoid classes such as lipoxins, 
prostaglandin E2 and leukotriene B4 that have the ability to limit the extent and duration of the 
inflammatory process and promote the resolution of inflammation [59]. 
Low n-3 intake is a common characteristic of the Western diet due to low intakes of foods 
such as fatty fish and nuts [65]. N-6 FAs are consumed at a disproportionately high level in a 
standard western diet compared to n-3 due to high intakes of meat, processed foods, soy and corn 
oils [52]. Although both FAs are considered essential, it is important to maintain a reasonable 
ratio between n-6 and n-3 FAs in the diet because they compete for the same enzyme complex 
(PLA2) for conversion to their respective long chain derivatives [66]. The bioavailability of 
PUFAs and their bioactive derivatives depends on diet composition with an ideal ratio of 4 (n-
6):1 (n-3) to 5:1 [67]. However, a typical Western diet pattern tends to contain 14 to 25 times 
more n-6 FAs than n-3. This imbalance can result in inappropriately elevated or sustained 
inflammatory conditions. 
 
PUFAs in the Brain 
The brain is the second-most fatty organ next to adipose tissue. Due to high phospholipid 
content, approximately 60% of the brain’s dry weight consists of lipids with about 30% of that 
lipid consisting of PUFAs and 5-10% as AA [68]. Brain phospholipids form the membrane lipid 
bilayers of neurons, glia and cerebrovascular cells. Normal physiological functioning of the 
neuronal membrane is highly dependent on its structure. Membrane lipids indirectly control a 
variety of biological functions through their regulation of enzymes, receptors and 
neurotransmitters. Therefore, any alteration in lipid content has a pivotal role on membrane 
properties and can induce functional changes [69]. As opposed to triglycerides, PUFAs are 
preferentially incorporated by phospholipids with the majority of the PUFAs in cell membranes 
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synthesized from LA and ALA [70, 71]. In fact, up to 60% of lipids incorporated in neural 
membranes consist of DHA, as it can easily pass through the BBB [72-74]. The neuronal cell 
membrane is in a constant state of flux as FAs are released from the membrane by 
phospholipases. Types of FAs consumed in the diet determines the FAs that are available for the 
composition of cell membranes. Increased consumption of n-3 PUFAs results in a partial 
replacement of AA by DHA in the neuronal cell membrane [75]. Conversely, lower n-3 intake 
leads to lower brain levels of DHA with increased AA levels.  
 
N-3 FAs in the Brain 
Incorporation of n-3 FAs into the phospholipid bilayer has a prominent role in maintaining 
membrane fluidity, which is important in regulating many membrane functions such as signal 
transduction, solute transport and enzyme activity [76, 77]. Inadequate n-3 intake can result in 
neuronal cell membranes with increased straight-chain SFAs, which decrease membrane fluidity 
and consequently alter these functions. N-3 FAs can also directly modify neurotransmitter 
production, accumulation, release and re-uptake. For example, rats with n-3 deficiency had 
significantly decreased dopamine content and storage in the frontal cortex, suggesting that 
alterations in n-3 intake may have an impact on dopamine synaptic neurotransmission and 
plasticity [78-80]. Interestingly, n-3 supplementation was able to increase dopamine levels in 
those same areas, hinting at a possible therapeutic effect [81]. 
DHA is especially essential during pre- and post-natal human brain development. Being 
prevalent in grey matter and synapses, DHA deficiency can include consequences such as 
cognitive impairment and diminished visual acuity [82]. Relationships between n-3 FAs and 
neurological disorders and diseases have been extensively researched. Severe restriction of n-3s 
usually correlates with anxiety-like behavior and a deficit in cognitive functions, including 
memory and learning. Diets low in n-3s have been linked to neuroinflammation and the 
development of neurological disorders such as depression, bipolar disorder, schizophrenia and 
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Parkinson Disease [83-86]. These findings have led to the investigation of the neuroprotective 
effect of n-3. 
 
N-6 FAs in the Brain 
Necessary for cell membrane integrity, AA is the second most predominate PUFA in the 
brain. In addition to DHA, AA likely enters the brain by free diffusion across the cell membranes 
of the BBB. AA has a much shorter half-life (five months) compared to DHA (two years) [87]. 
Therefore, it has been estimated that the brain needs 18 mg of AA per day. Animal models have 
suggested AA may be beneficial in neuroinflammatory diseases by attenuating amyloid β 
deposition and improving cognition [88, 89]. However, results have not been consistently 
replicated. 
Conversely, AA may also have detrimental effects in the brain. These FAs in the neuronal 
cell membrane are metabolized to different eicosanoids by COX/LOX pathways which are 
involved in the neuroinflammatory process. In neurological diseases such as Parkinson Disease, 
organisms are not able to buffer PUFA concentrations. Therefore, with higher consumption of 
LA, higher amounts of AA may be incorporated into neuronal cell membranes and ultimately 
result in increased neuroinflammation and neurological diseases. 
 
Saturated Fatty Acids (SFAs) 
SFAs are straight-chain organic 
acids that make up 10-40% of the total 
fatty acids in most natural lipids and can 
also be synthesized by the body (Figure 
3). Not only are they a source of fuel and 
structural components of cell 
membranes, but various SFAs are also associated with proteins and are necessary for their normal 
 
Figure 3: Chemical Structure of Saturated Fatty Acids 




function. SFAs do not contain double bonds and are named and abbreviated systematically from 
the saturated hydrocarbon with the same number of carbon atoms. In addition to systematic 
names and abbreviations, each SFA may also be referred to by its trivial or common name (Table 
4). Currently, there are no recommendations for daily intake as the IOM notes no evidence of 
SFAs being essential in the diet or having beneficial roles in the prevention of chronic diseases. 
However, prominent organizations like the American Heart Association recommend less than 
10% of total fat calories per day as saturated fat, or less than 4.4 to 7.7 grams per day based on a 
2000 calorie per day diet, irrespective of chain length.  
Table 4: SFA Trivial Names, Systemic Names and Abbreviations by Chain Length Subcategory 
SFA Subcategory Trivial Name Systematic Name Abbreviation 
SCFA 
Acetic Acetate C2:0 
Propionic Proprionate C3:0 
Butanoic Butyrate C4:0 
Caproic Hexanoic C6:0 
MCFA 
Caprylic Octanoic C8:0 
Capric Decanoic C10:0 
Lauric Dodecanoic C12:0 
LCFA 
Myristic Tetradecanoic C14:0 
Palmitic Hexadecanoic C16:0 
Stearic Octadecanoic C18:0 
Arachidic Eicosanoid C20:0 
Behenic Docosanoic C22:0 
Linoceric Tetracosanoic C24:0 
SFA: Saturated fatty acid; SCFA: Short-chain saturated  fatty acid; MCFA: Medium-chain saturated 
fatty acid; LCFA: Long-chain saturated fatty acid 
 
Although the compounds are historically thought of as one group, evidence shows SFAs with 
different physical and chemical structures have different metabolic and health effects [90, 91]. In 
appreciation of their differences, SFAs are often comprised into three sub-groups: short chain 
(C2:0-C6:0), medium chain (C8:0-C12:0) and long chain (C14:0-C24:0) FAs.  
Short-chain saturated fatty acids (SCFAs) are small, monocarboxylic acids with a chain 
length of up to six carbon atoms and are the main products of anaerobic fermentation of 
indigestible dietary fibers, proteins and resistant starch in the large intestine [92]. The SFA group 
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is comprised of acetate (C2:0), proprionate (C3:0), butyrate (C4:0) and hexanoic (C6:0) acids 
[93]. Approximately 500-600 mmol of SCFAs are produced in the gut per day depending on the 
fiber content in the diet, intestinal bacteria and intestinal transit time [94]. Aside from 
fermentation, sources of butyrate include milk fat [95] and acetate produced from acetyl-CoA 
derived from glycolysis [96, 97]. The highest levels of SCFAs are found in the proximal colon, 
where they are utilized locally by enterocytes or transported across the gut epithelium into the 
bloodstream [98]. 
SCFAs are mobilized to improve intestinal health through a number of local effects, ranging 
from maintenance of intestinal barrier integrity, reduction of oxidative stress, protection against 
inflammation and modulation of the mucosal immune response to reduction of the risk of 
colorectal cancer [99-102]. The production of SCFAs through increased intake of dietary fiber to 
enhance these beneficial characteristics has been an attractive intervention in the field of 
gastrointestinal diseases. However, recent research also indicates that increased SCFAs intake 
and/or fermentation is advantageous in the brain by playing a pivotal role in the gut-brain axis 
[103-105]. The gut-brain axis describes the close connection and tight bidirectional 
communication between the intestinal tract and brain and the importance of their cross-talk for 
brain functions in health and disease [106]. 
SCFAs bind to several G protein-coupled receptors (GPR) which results in secretion of 
glucagon-like peptide 1 and signals the pancreas to increase insulin secretion. Dietary butyrate 
(C4:0) supplementation enhances FAO in mice and both butyrate and proprionate (C2:0) have 
been shown to inhibit high fat diet-induced weight gain [107, 108]. SCFAs are also histone 
deacetylase inhibitors (HDACis) which promote the acetylation of lysine residues present in 
histones in various cell populations, including neurons.  
MCFAs comprise SFAs with 6 to 12 carbons: hexanoic (C6:0) octanoic (C8:0), decanoic 
(C10:0) and dodecanoic (C12:0) acids. Major suppliers of MCFAs are coconut, palm kernel and 
Cuphea species oils and dairy fats. Besides natural sources, MCT oils, produced by hydrolysis of 
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one of the aforementioned oils, contains almost exclusively octanoic (C8:0) and decanoic (C10:0) 
acids at a ratio of 50:50 to 80:20 [21].  
Triglycerides containing MCFAs are broken down almost immediately by enzymes in the 
saliva and gastric juices without using pancreatic fat-digesting enzymes. As MCFAs does not 
depend on proteins for binding, transport and transmembrane location, the FAs are absorbed 
quickly and efficiently in the intestinal lumen [21]. Their ability to be absorbed outside of the 
lymphatic system allows MCFAs to be utilized as a calorie and fat source in many digestive 
abnormalities such as fat malabsorption. Studies have demonstrated that MCFAs modulate 
carbohydrate and lipid metabolism, as well as mitochondrial energy production [109]. MCFAs 
are more rapidly β-oxidized compared to LCFAs and do not appear affected by the carbohydrate 
content in the diet [110]. St-Pierre et al. showed oral MCFA supplementation was able to raise 
plasma MCFA and KB concentration in humans eating a carbohydrate-rich diet. [111]  
Long-chain saturated fatty acids (LCFAs) contain over 12 carbons and constitute the greatest 
bulk of FAs in animal diets. Palmitic acid (C16:0) and stearic acid (C18:0) are considered the 
most abundant SFAs in nature comprising 20-30% and 10-20% of lipids in animal tissues and 
lipid classes, respectively. Additional LCFAs present in lower amounts of a human diet include 
Myristic acid (C14:0), Arachidic acid (C22:0), Behenic acid (C22:0) and Linoceric acid (C24:0). 
LCFAs are an important source of energy in tissues and are essential to the structure and function 
of lipid membranes. In contrast to SCFAs and MCFAs, LCFAs require fatty acid-binding proteins 
for their cellular uptake, intracellular transport, regulatory functions and metabolism [112]. 
LCFAs are esterified to triglycerides in enterocytes, incorporated into chylomicrons and then 
enter the lymphatic system.  
LCFAs are often associated with negative health effects such as insulin resistance, generation 
of reactive oxygen species (ROS) and inflammatory responses in the body [113, 114]. Palmitic 
acid (C16:0) can activate inflammatory pathways directly by stimulating macrophages to produce 
cytokines via toll-like receptors (TLR) 2 and 4 and by stimulating signaling molecules as protein 
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kinase R. Excessive LCFAs levels are believed to contribute towards lipotoxicity and 
neuroinflammation [115]. 
 
SCFAs in the Brain 
The gut microbiota has been shown to significantly influence central nervous system 
physiology and neurochemistry [116]. Intestinal dysbiosis has been identified in many 
neurological diseases, including Parkinson’s disease and Alzheimer’s disease [117, 118]. As 
stated previously, SCFAs are the main energy source for endothelial cells and have a role in 
preventing or ameliorating microbiome dysbiosis [107]. Therefore, relationships between 
butyrate, the gut-brain axis and neurological outcomes are being explored.  
SCFAs appear to influence neuronal function by modulating levels of neurotransmitters and 
neurotrophic factors which support the growth, survival and differentiation of developing and 
maturing neurons [119]. SCFAs are also able to cross the BBB and play an important role in 
maintaining its integrity and even ensuring permeability [120, 121]. 
Butyrate (C4:0) is part of a class of epigenetic modulators known as HDACis which have 
been identified as a possible treatment option for neurodegenerative diseases [122, 123]. The 
branched chain SCFA, valproic acid (VPA), is another HDACi and a commonly used broad-
spectrum ASM [124]. Although effective, VPA therapy has been considered sub-optimal due to 
numerous side effects [125]. Oral sodium butyrate (NaB) supplementation has been shown to 
protect neurons from cell death in models of Parkinson’s disease and decrease the infarct size in 
models of ischemic stroke, which limits the damage to the brain and improves behavioral 
outcomes [122, 126]. In vitro and in vivo data suggest butyrate can induce resistance to oxidative 
stress and increase histone acetylation [127]. Together, these observations are consistent with the 
theory that butyrate can modulate the expression of a large number of genes which may affect 




MCFAs in the Brain 
In addition to DHA and SCFAs, MCFAs are also able to cross the BBB and may have brain 
health benefits by modulating brain metabolism [128]. KBs derived from MCFAs have been 
shown to improve cognition in patients with Alzheimer’s disease and attenuate neurodegeneration 
in an animal model of amyotrophic lateral sclerosis [129].  
Although a majority of dietary MCFAs are converted to KBs, studies have shown that they 
also have diverse effects on cognitive and neuronal function [130]. For example, MCFAs had 
differential effects on synaptic stability, protein synthesis and cognitive behavior in Wistar rats 
that may be independent of ketone levels [131]. The ability of MCFAs to improve cognitive 
function has also been reported with improvement seen in patients with Alzheimer’s Disease 
[132]. MCFAs reduce amyloid β-production and deposition in the brain and activate G-protein 
coupled receptors (GPR), which are highly expressed in the brain and have roles in glucose 
regulation and inflammation [133, 134].  
Recent research proposes MCFAs have anti-seizure effects at clinically relevant 
concentrations in vitro and in vivo, suggesting they directly contribute to the therapeutic effect of 
the MCTKD [135, 136]. Preliminary evidence suggests MCFAs may be able to impact seizure 
activity independent of a carbohydrate restricted diet. 
 
LCFAs in the Brain  
As previously mentioned, excessive LCFAs have a significant impact on inflammation in the 
human body. Specifically, LCFAs increase proinflammatory cytokine expression in astrocytes 
and the microglia [137]. The brain is highly sensitive to inflammatory mediators and there is 
ample data to indicate that cytokines can have clinically significant adverse effects on cognition 
and neuronal homeostasis [138]. In fact, LCFAs have been explicitly implicated in the 
development of neuroinflammatory diseases [137, 139, 140]. 
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In addition to neuroinflammation, LCFAs have been shown to modulate amyloid processing 
in neurons and astrocytes, increase α-synuclein and tyrosine hydroxylase levels and reduce the 
expression of insulin-degrading enzyme which is implicated in the pathogenesis of Alzheimer’s 
Disease [139, 140]. Together, these data indicate excess intake and production of LCFAs appear 
to have a detrimental effect and brain function and likely perpetuate neurological disease.  
 
Theorized Anticonvulsant Properties of FAs 
Current literature suggests PUFAs and SFAs may elicit anticonvulsant properties through one 
or more theorized mechanisms of action: modification of neuronal cell signaling and 
hyperexcitability, mediation of neuroinflammation, activation of peroxisome proliferator-







Figure 4: Theorized Anticonvulsant Properties of Fatty Acids 
(FAs): Mediation of Neuronal Cell Signaling and Hyperexciatbility, 
Mediation of Neuroinflammation, Activation of Peroxisome 
Proliferator-Activated Receptors (PPAR) and Inhibition of Histone 














Modification of Neuronal Cell Signaling and Hyperexcitability 
Seizures often occur when a disruption in the normal balance of excitation and inhibition 
occurs. Normally, there are controls that keep neurons from excessive action potential discharge, 
but there are also mechanisms that facilitate neuronal firing so the nervous system can function 
properly. Disrupting the mechanisms that inhibit firing or promoting the mechanisms that 
facilitate excitation can lead to seizures [141]. However, seizure activity may be prevented by 
disrupting the mechanisms that bring neurons close to their firing threshold, or enhancing the 
ways neurons are inhibited. The incorporation of select PUFAs and SFAs into the neuronal cell 
membrane may have a significant impact on action potentials through modulation of voltage 
gated channels and conductance of currents [142-145]. Here, n-3 PUFAs, specifically DHA, 
along with SCFAs and MCFAs show an ability to modify neuronal cell signaling and 
hyperexcitability, potentially inhibiting seizure onset or potentiation.  
Landmark studies in the 1990’s by Xiao et al. and Vreugdenhil et al. showed PUFAs are able 
to stabilize the neuronal membrane by suppressing and causing a significant shift in steady state 
inactivation for voltage-gated Ca2+ currents and Na+ channels [142, 146, 147]. ASMs including 
carbamazepine, phenytoin and valproate have very similar actions on Na+ channels which 
provides evidence that these actions significantly contribute to anti-seizure functions [124, 148]. 
A later study by Xiao et al. also found that DHA, specifically, could raise the action potential 
depolarization threshold and decrease the frequency of stimulus‐evoked action potentials [143]. 
This may be explained by the ability of DHA to suppress conductance of currents in neuronal 
cells and reduce neuronal hyperexcitability [143, 147, 149-152].  
In further support of FAs inhibiting seizure activity via this theorized mechanism of action, 
SCFAs and MCFAs appear to modify cell signaling and neuronal hyperexcitability [145]. Acetate 
(C2:0) has previously been shown to alter the levels of the neurotransmitters glutamate, glutamine 
and gamma-aminobutyric acid (GABA) in the hypothalamus [153]. Furthermore, propionate 
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(C3:0) and butyrate (C4:0) exert an influence on intracellular potassium levels, implying their 
involvement in the operation of cell signaling systems [154]. MCFAs have been shown to act on 
phosphoinositide signaling in seizure control in a similar, but more potent mechanism to VPA 
[155]. Furthermore, MCFAs have shown anticonvulsant activity via direct inhibition of the α-
amino-hydroxyl-5-methyl-4-isoxazoleproprionic acid (AMPA) receptor [144]. Inhibition of this 
receptor is the mechanism behind the currently available and widely used ASM, perampanel. 
AMPA receptors play a key role in generating and propagating epileptic activity. In addition to 
mediating synchronous epileptic discharges from the seizure origin, AMPA receptors are 
critically important in the spread of seizure activity locally and to distant brain regions. Data 
indicate that 100 µmol/L decanoic acid (C10:0) results in a 3-fold increase in the inhibition of the 
AMPA receptor.  
 
Mediation of Neuroinflammation  
Neuroinflammation is characterized by an increased inflammatory response, centralized in 
the brain and spinal cord. Harmful downstream effects of sustained neuroinflammation can lead 
to the development of dementia and a number of neurological diseases, including Parkinson 
Disease and Amyotrophic Lateral Sclerosis [156, 157]. Neuronal damage and the unhalted 
progression of neuroinflammation may also lead to epilepsy onset or potentiate recurrent seizure 
development (epileptogenesis) through extra-hippocampal neuronal cell death and microglial cell 
activation [151, 152, 158].  
Cytokine levels have been suggested as predictors of the beginning of spontaneous seizures 
as both Interleukin (IL-) 6 and Tumor Necrosis Factor alpha (TNF-α) levels are increased in 
microglial cells after epileptic seizures [159]. An overexpression of these cytokines leads to a 
decrease in seizure threshold and an increase in spontaneous seizure frequency by participating in 
neuronal hyperexcitability through alterations in ion channels and glutamate production [160-
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163]. PUFAs and SFA are potent regulators of neuroinflammation with n-3 FAs, SCFAs and 
MCFAs often thought of as having anti-inflammatory properties.  
Deprivation of n-3 FAs has been shown to decrease levels of DHA and increase markers of 
brain AA, and neuroinflammation [86, 164]. SPM from DHA and EPA are produced in a dose-
dependent manner in the brain to counteract and resolve neuroinflammation by exerting pro-
survival, neuroprotective capabilities and preventing apoptosis induced by oxidative stress [165-
167]. In pre-clinical studies, animal models treated with SPM, including MaR1, RvD1, RvD2 and 
Neuroprotetin D1 (NDP1), have decreased cytokine (TNF-α, IL-6, IL-1β) levels, decreased 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) protein and decreased 
COX-2 expression [168-173]. Additionally, separate studies have reported treatment of brain-
injured animal models with RvD2 and MaR1 inhibit microglial activation, therefore decreasing 
neuroinflammation [171, 172]. In 2018, Frigerio et al. showed that injecting mice with DHA-
derived protectin D1 during epileptogenesis, reduced both neuroinflammation and the frequency 
of spontaneous seizures by half and the time spent in seizures by three-fold [174]. A significant 
upregulation in both inflammation and SPM at 72 hours supports the hypothesis that 
neuroinflammation in epileptogenesis may progress without adequate SPM substrate. 
Specifically, cumulative levels showed a downregulation of DHA-derived resolvins and AA-
derived lipoxins and an upregulation in DHA-derived protectins and EPA-derived resolvins 
[174].  
SCFAs also appear to have a significant impact on regulation of neuroinflammation. Several 
studies have reported that oral NaB is able to decrease microglial activation and pro-
inflammatory cytokine secretion [123, 175, 176]. Furthermore, there is some evidence that 
suggests butyrate’s (C4:0) antioxidant activity decreases the level of reactive oxygen species 
(ROS) while increasing glutathione [177]. Butyrate treatment in vivo and in vitro induces changes 
in the microglia and inhibits pro-inflammatory modifications [175]. Similarly, in vivo SCFA 
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treatment and supplementation has been shown to decrease microglial activation in astrocytes and 
reduce inflammatory signaling through reduced IL-1β, IL-6 and TNF-α expression and NF-kB 
phosphorylation [178-180]. The role of intestinal dysbiosis and intestinal inflammation in 
reducing seizure threshold or aggravating seizures has also been previously reported and 
confirmed in a colitis animal model [181, 182]. Consequently, SCFA may also provide anti-
inflammatory properties by preventing or attenuating intestinal dysbiosis and intestinal 
inflammation. 
 
Activation of Peroxisome Proliferator-Activated Receptors (PPARs)  
PPARs are members of the nuclear receptor family and are critically involved in the 
regulation of numerous genes that regulate energy homeostasis. When activated, PPAR isoforms 
(PPARα, PPARβ and PPARγ) act as agonist-activated transcription factors that regulate specific 
target gene transcription. PPARγ, in particular, has garnered significant interest in the potential 
neuroprotection in diverse neurodegenerative diseases, including epilepsy [183]. PPARγ is a 
master regulator of adipogenesis, lipid and glucose metabolism, and insulin sensitivity [184]. 
PPARγ also regulates anti-inflammatory, anti-oxidant and mitochondrial genes [185, 186]. It is 
primarily located in the nucleus of cells in the hippocampus and regulates the activation of 
microglial cells, suggesting that PPARγ agonists may impact neuroinflammation. PPARγ 
activation is initiated by ligand binding from a wide variety of naturally occurring 
monounsaturated FA, SFA, PUFAs, eicosanoids, and oxidized lipid agonists [187]. In humans, 
PPARγ exists in multiple isoforms (PPARγ1, PPARγ2 and PPAR-γ4) [188]. PPARγ1 is found 
universally, while PPARγ2 is restricted to adipose tissue. PPARγ2 is induced during high fat diets 
and has been shown to be differentially regulated between genotypes [189-191]. It is the only 
PPARγ isoform regulated at the transcription level by nutrition and activation stimulates the 
transcription of genes involved in fatty acid oxidation [192, 193].  
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Hung et al. found activation of PPARγ in mice significantly reduced sustained time of stage 
4-5 seizures, percentage of status epilepticus, and mortality due to seizures in mice [194]. Authors 
concluded PPARγ deficiency aggravated neuronal excitability and excitotoxicity. Conversely, the 
presence of PPARγ attenuated seizure severity, neuronal loss, BBB impairment and sodium 
currents in hippocampal neurons. Simeone et al. reported that administering PPARγ to epileptic 
knockout (KO) mice increased PPARγ2 expression by 2-fold (P < 0.01) and reduced seizures by 
80% (P < 0.01) [195]. Indeed, pretreatment with a PPARγ agonist prior to induced status 
epilepticus can inhibit neuronal cell death, which is a principal cause of acute and chronic 
neurodegenerative disease [196]. PPARγ antagonism has also been found to directly interfere 
with the anti-seizure mechanism of the cKD. KDT of normal mice increases PPARγ in the brain 
[195, 197]. However, a cKD was unable to raise the seizure threshold of PPARγ2 KO mice and 
conditional neuron-specific PPARγ KO mice, indicating the loss of PPARγ may exacerbate 
markers of injury and possibly seizures.  
N-3 PUFAs have features that allows optimal binding to PPARs. Previous studies have 
shown n-3 supplementation significantly upregulated gene expression of PPARγ specifically in 
humans with neurological disease [198-200]. While SFAs are PPARγ agonists, they generally 
considered poor ligands in comparison to long chain PUFAS [201, 202]. However, the MCFA 
decanoic (C10:0) acid is a recognized PPARγ agonist with a binding pocket which is drastically 
different from that of PUFAs [130]. A dramatic increase in MCFAs through dietary intervention 
or supplementation may be able to increase binding, resulting in anticonvulsant effects. 
 
Inhibition of Histone Deacetylase (HDAC) Dysregulation 
Previous studies have demonstrated that epigenetic signaling is essential in the progression of 
epileptogenesis and chronic epilepsy [203]. Histone acetylation has been widely linked to 
transcriptional activity and is regulated by opposing actions of two classes of enzymes: histone 
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acetyltransferases, which facilitate histone acetylation and activate gene transcription and 
HDACs, which suppress gene transcription and gene expression [204]. HDAC inhibition 
upregulates the expression of brain-derived neurotrophic factor, which is responsible for the 
activation of multiple proteins involved with neuronal biogenesis and cognition [205, 206]. 
Conversely, HDAC dysregulation may lead to impaired acetylation and deacetylation resulting in 
the development of neurological diseases, including epilepsy. Specific histone modifications, H3 
and H4 phosphorylation, have been reported in several animal seizure models [207-209]. 
Therefore, inhibiting epigenetic changes in histone acetylation may be a key step in preventing or 
halting epileptogenesis.   
The SCFAs butyrate (C4:0) and VPA are able to inhibit HDACs, subsequently offering 
neuroprotective benefits to the brain by enhancing acetylation of histones, restoring the balance of 
histone acetylation and adjusting transcriptional dysfunction [210, 211]. NaB behaves similarly to 
VPA, but inhibits a wider range of HDAC classes (1, 2 and 7) compared to VPA (classes 1 and 2 
only) [212]. Supplementation has previously been shown to inhibit HDACs and increase the 
acetylation of H3 and H4 histones in the brain [213, 214]. In fact, NaB significantly increased H3 
and H4 acetylation in comparison to VPA [215]. Thus, increasing butyrate (C4:0) intake through 
dietary intake, supplementation or endogenous production may be beneficial in individuals with 
epilepsy.  
 
Anticonvulsant Effects of PUFAs and SFAs in Animals and Humans  
Data suggests that FAs, specifically n-3, SCFAs and MCFAs, have the potential to increase 
seizure thresholds and prevent or halt epileptogenesis. Proposed mechanisms of action have 





Anticonvulsant Effects of PUFAs in Animal Models 
Pre-clinical trials have regularly shown PUFAs may have anticonvulsant properties, but 
results have not been consistently replicated in clinical trials [68, 216, 217]. Early animal models 
reported on the anticonvulsant effects of ALA and LA and their ability to increase latency to 
seizure onset [218-221]. However, when unsuccessful attempts were made to replicate these 
studies, researchers hypothesized that increased doses of PUFA’s may be needed to elicit anti-
seizure effects [222, 223]. In support of this hypothesis, investigations by Taha et al. and Porta et 
al. found higher-dose PUFA administration (200 mg/kg intraperitoneal and 60000 mg/kg gavage, 
respectively) increased seizure thresholds in animal models with PTZ induced seizures [39, 224].  
When assessed separately and dose-dependently, DHA (100-300 mg/kg), but not EPA, raised 
seizure thresholds [225, 226]. In mice, acute administrations of DHA at dosages of 65 mg/kg or 
higher raised seizure thresholds with levels, but effects were not sustained after one hour [68, 
221, 227]. In another positive trial, Trepanier et al. treated Wistar rats with 50 mg/kg DHA or 
saline for 14 days followed by seizure induction [228]. Here, a lower DHA dose significantly 
increased seizure latency by approximately three-fold as compared to controls when provided 
over an extended period of time.   
Animal studies indicate that single or insufficient dosing may explain some variability in pre-
clinical trials. In addition, researchers suggest a minimum of three months of dietary n-3 
supplementation is required to raise seizure thresholds [226]. Chronic consumption has been 
shown to increased concentrations of unesterified EPA and DHA in the brain by two-fold, 
suggesting time is an important factor in n-3 dosing. Increased concentrations of EPA and DHA 
in the brain may provide adequate substrate to elicit anticonvulsant properties or result in a shift 






Anticonvulsant Effects of PUFAs in Clinical Trials 
Early clinical trials of n-3 supplementation in subjects with epilepsy were largely positive. In 
a 2002 study, Schlanger et al. saw a significant reduction in seizure frequency and strength after 
six months of 3.25 g n-3 (0.9 gm EPA and 2.3 gms DHA) per day [229]. Unfortunately, only five 
patients completed the study due to the taste of the oral fish oil spread. Nonetheless, the study 
provides optimism in the ability of high dose, long-term n-3 supplementation to provide 
therapeutic benefit to epileptic patients.  
A 12-week placebo-controlled parallel group study published in 2005 provided 1 gm EPA 
and 0.7 gm DHA per day to the intervention group. Here, Yuen et al. reported 17% of subjects 
receiving supplementation had at least a 50% reduction in seizures during the first six weeks 
[230]. Supplementation also resulted in significant increases of serum EPA and DHA 
concentrations and associated decreases in LA and AA concentrations, mirroring results from 
KDT and animal studies. The same group followed up in 2011 with a non-randomized open 
assessment of 10 subjects with refractory focal seizures receiving 1000 mg EPA per day for three 
months. Compared to baseline, six subjects had fewer seizures while receiving supplementation 
with one subject reporting markedly reduced seizure severity. Mean reduction in seizure 
frequency was 16% (p = 0.26). Although results from these two groups are encouraging, small 
sample sizes and subjective seizure reporting limit the validity and reproducibility of the data.  
In disagreement, two studies published in 2008 reported no beneficial effect of PUFA 
supplementation in reducing seizure frequency or severity. A double-blind, placebo controlled 
RCT by Bromfield et al. supplemented adult refractory epilepsy patients with 2.2 mg EPA plus 
DHA in a 3:2 ratio (1.32 g EPA and 0.88 g DHA) for 12 weeks [231]. Negative results from this 
study include two subjects on placebo versus none on n-3 supplementation experiencing a 50% 
decrease in seizure frequency. Furthermore, median seizure frequency increased by 6% in the 
intervention group (n=12) and decreased by 12% in the placebo group (p = 0.21). In a 
prospective, randomized, 3-period crossover trial of two doses of fish oil, DeGiorgio et al. 
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exposed subjects with partial-onset seizures to each PUFA treatment group (high-dose, low-dose 
and placebo) for 10 weeks [232]. The low-dose group received a total n-3 dose of 1080 mg/day 
(648 mg EPA, 432 mg DHA) and the high dose group received 2160 mg/day (1296 mg EPA, 865 
mg DHA). For those receiving low-dose fish oil, 5/20 experienced a 50% seizure reduction as 
compared with placebo with two subjects becoming seizure free. No differences were observed 
when comparing high-dose fish oil to placebo. Authors surmised that patients receiving lower 
doses of n-3 FAs have improved efficacy over high-doses. This and previous studies have 
suggested that high doses of n-3 FAs do not exhibit anticonvulsant effects due to the suppression 
of AA levels [230]. However, significant limitations of this trial, to include the crossover design 
and short exposure period, minimize the ability to conclude low-dose fish oil supplementation is 
superior to high-dose supplementation.  
Three studies published in the past decade have not only report positive findings, but also 
begin to elucidate the n-3 mechanism of action in human subjects. First, a clinical trial published 
in 2010 by Al Khayat et al. studied serum levels of PUFAs and therapeutic response in 20 
Egyptian children with idiopathic intractable epilepsy [233]. Prior to supplementation, subjects 
had lower levels of DHA and higher levels of ALA, EPA and LA compared to healthy controls as 
assessed by gas liquid chromatography. After six months of oral PUFA supplementation, levels 
of DHA were increased while ALA, LA, EPA and AA were decreased. Furthermore, there was an 
improvement in n-6:n-3 and increased DHA:EPA ratios. Changes in serum levels of PUFAs and 
their ratios were accompanied by a decrease in seizure frequency, duration and severity. A 
significant negative correlation between serum DHA and seizure duration and seizure severity 
was reported. Next in 2015, Reda et al. conducted a case control study investigating the effect of 
1200 mg (720 mg EPA and 480 mg DHA) n-3 as fish oil per day to Egyptian children with 
epilepsy [234]. Subjects (n=70) had a median number of four seizures per month prior to 
supplementation. The median seizure occurrence decreased in the intervention group (n=35) to 
two seizures after one month. The median again decreased to zero seizures in both months two 
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and three of supplementation (p < 0.05). No significant difference in the medians of seizure 
severity was observed. Finally, a recently published triple-blind, placebo-controlled parallel 
group trial by Omrani et al. supplemented n-3 PUFAs to 50 subjects with refractory epilepsy 
[235]. Those in the intervention group received 180 mg EPA and 120 mg DHA twice per day 
(360 mg EPA and 240 mg DHA total) for 16 weeks. Seizure frequency and duration in addition to 
TNF-α and IL-6 were significantly lower in the supplement group with corresponding improved 
electroencephalogram (EEG) patterns.  
Conflicting results from clinical trials, not unlike animal models, may be explained by 
variations in n-3 dosing and duration of supplementation. Although total PUFA levels increase in 
plasma following oral administration, initially the majority of the elevated PUFA subtypes are 
probably trapped in the chylomicron/LDL pools. Auvin et al. claims PUFA subtypes probably do 
not appear in its unesterified form in plasma until the chylomicron/LDL pool is eventually 
saturated [216]. Depending on the age and baseline diet of the patient, supplemental doses of n-3 
may need to be higher than the 1.1 to 3.2 gms per day that have been used in previous clinical 
trials. Specifically, it has been widely demonstrated that the effective dose in other neurological 
disease is 1 g/day of DHA from animal or algal sources [83, 236]. This higher dosage likely 
needs to be continued over an extended period of time to ensure unesterified n-3 is reaching the 
brain. 
Aside from discrepancies in dose and duration, another factor to consider in these trials may 
be the relationship of long-term diet exposure on seizure outcomes. As previously discussed, n-6 
intake significantly outweighs n-3 intake in a typical Western diet. Recently published data show 
prolonged intake of a pro-inflammatory diet can alter gene expression and metabolism [237, 238]. 
Currently, there is a paucity of data describing the impact of typical dietary intake on seizure 





Anticonvulsant Effects of SFAs Animal Models 
The majority of research on the impact of SCFAs in epilepsy is centered on the epigenetic 
mechanism of butyrate (C4:0) as an HDACi. In an animal epilepsy model in 2017, Reddy et al. 
showed treatment of SCFAs as NaB (600 mg/kg, i.p.) twice daily for two weeks markedly 
decreased the development of spontaneous seizures with a corresponding increase in H3 and H4 
acetylation and reduced HDAC activity in the hippocampus [239]. Citraro et al. provided mice 
oral treatment of NaB (30 mg/kg/day), VPA (600 mg/kg/day) or a combination to rats for 17 
weeks prior to seizure onset [240]. Researchers showed long-term oral supplementation was able 
to significantly reduce seizure development and inhibit epileptogenesis. Here, H3 acetylation was 
significantly increased by both treatments while H4 acetylation was only significantly increased 
by NaB. Finally, Li et al. evaluated the effect of smaller doses of NaB (5, 10, and 20 mg/kg, 
intraperitoneally) for 40 days prior to seizure induction [241]. Again, a significant reduction in 
seizure score and significantly longer latencies in seizure development were seen in all three 
groups. Interestingly, the 10 mg/kg dose appeared most effective. Here, NaB exhibited 
neuroprotective qualities by rescuing seizure-induced neuronal loss and apoptosis in the 
hippocampus. Supplementation also led to an increase in antioxidant enzyme activity and reduced 
ROS levels, hinting at the potential of an anti-inflammatory effect of SCFAs.  
Although data suggest intestinal inflammation may perpetuate seizure activity and SCFAs 
may mediate this inflammation, studies directly relating SCFA to seizure activity are rare. 
Recently, De Caro et al. studied the intestinal inflammation on PTZ-induced seizures in mice 
mice fed NaB at 100 mg/kg per day. Not only was the SCFA significantly effective in increasing 
seizure thresholds, it also elicited significant protective effects against intestinal inflammation. 
This study substantiated the hypothesized link between SCFAs and epilepsy.  
The efficacy of the MCTKD in subjects with epilepsy has launched investigations into the 
anticonvulsant properties of MCFAs. The first study to assess the impact of MCFAs in vivo was 
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published in 1990 by Nakamura et al. [242]. The group administered MCFAs i.p. at two doses 
(0.5 and 1.0 mmol/kg) in mice 15 minutes before seizure induction and found decanoic acid 
(C10:0) at 1.0 mmol/kg delayed the onset to clonic convulsions and increased the survival to 
lethality induced by induced seizures. Since 1990, studies have consistently shown the MCFAs 
octanoic (C8:0) and decanoic (C10:0) acids have anticonvulsant effects and are effective during 
seizure induction [135, 243]. In 2015, Wlaz et al. administered oral doses of MCFAs to albino 
Swiss mice prior to seizure induction [136]. Here, decanoic acid (C10:0) dose-dependently (1.7-
8.6 g/kg) increased seizure thresholds. Both octanoic (C8:0) and decanoic (C10:0) acids at 1.4-4.3 
g/kg, respectively produced comparable increases in seizure thresholds. When administered 
together, seizure thresholds increased even further, suggesting an additive interaction or 
symbiotic relationship between the MCFAs. 
In another 2015 study, Chang et al. assessed if acute anti-seizure effects of the MCTKD were 
related to a direct effect of KBs or MCFAs [144]. Here two in vitro models showed KBs did not 
have any effect on epileptiform activity while an MCFA (decanoic acid) completely blocked 
epileptiform activity in both models. This supports an anti-seizure effect of MCFAs in the 
MCTKD, rather than diet-derived KBs. This study also aimed to find a mechanism of action 
behind the anti-seizure effects of MCFAs and identified their ability to block AMPA receptors.  
A recent study by Tan et al. fed mice 35% of calories as MCFAs for 10 days prior to acute 
seizure tests [244].  Feeding MCFAs increased seizure thresholds in independent experiments 
compared to a control diet (both p <0.05). After 20 days of dietary treatment, blood and forebrain 
samples were collected from mice that had undergone seizure induction 10 days earlier to assess 
levels of glucose, BHB and MCFA levels. Plasma glucose levels were similar in all diet groups 
and neither plasma nor brain BHB were elevated in any diet group. However, oral MCFA intake 





Anticonvulsant Effects of SFAs in Clinical Trials 
To the best of our knowledge, no studies specifically investigating the impact of SFAs on 
epilepsy have been published. Although research evaluating probiotics and MCTs in humans are 
available, we are unable to verify if an outcome is due to a confounding factor such as GABA 





Animal and clinical studies appear to confirm proposed mechanisms of action suggesting 
therapeutic benefit of FAs in epilepsy. However, the ability of these FAs to elicit anti-seizure 
effects in individuals following a general diet has not been extensively studied. In this analysis, 
we aimed to provide insights into the effect of dietary PUFA and SFA intake on seizure presence 
and severity in a cohort of subjects admitted to an EMU. Our long-term goal is to identify targets 




CHAPTER 1: METHODS 
Study Design and Population 
The present study aims to explore the impact of dietary PUFA and SFA intake on seizure 
presence and severity in subjects with suspected or confirmed epilepsy. After obtaining approval 
by the Institutional Review Board (IRB) at the University of Nebraska Medical Center (Omaha, 
NE, IRB protocol #571-18-FB), prospective enrollment of a cohort of epileptic patients admitted 
to an epilepsy monitoring unit (EMU) at Nebraska Medicine in Omaha, Nebraska was completed.  
All patients admitted for management of refractory epilepsy in the EMU between May 2019 
and December 2019 were considered for enrollment. Inclusion criteria included patients of all 
ages deemed medically stable. Medical stability, determined by the admitting provider, was 
characterized as admission to the EMU under voluntary and non-emergent conditions.  
Those without capacity to provide informed consent, as determined by an assessment of 
cognitive status by Dr. Arun Swaminathan MBBS, patients who were not medically stable, 
patients consuming greater than 6000 calories per day, pregnant women, and prospective 
subjects/guardians who could not read or write English were excluded as the validated tool 
administered to subjects is only available in English.  
 
Procedure 
Medical staff/study personnel approached prospective subjects and informed consent on 
adults older than 19, parental consent on children less than 19, and child assent on children 7 to 
18 years of age was obtained. After enrollment, baseline and clinical data were collected from the 
electronic medical record (EMR) and a study packet containing the Harvard Food Frequency 
Questionnaire (FFQ), self-contained blood sampling devices (NoviPlex™ cards), fingerstick 
supplies and instructional materials was allocated to the subject. The duration of the study lasted 





The Harvard FFQ was utilized to determine dietary intake. This tool has been validated in 
adults of all ages and sexes and among a variety of socio-economic groups [245-249]. The FFQ 
consists of a list of foods and beverages that represent major contributors to the diet of the 
participants and frequency of how often each food is consumed. Specific information on the use 
of supplements and their contribution to fatty acid intake is part of the FFQ. From responses to 
the questionnaire, individualized nutrient intake can be calculated based on the known nutrient 
content of foods.   
Verbal education was provided on the approach to completing the FFQ and assistance was 
offered to those unable to answer the form independently. Completed FFQs were collected by 
study personnel and sent to the Harvard School of Public Health for nutrient analysis.  
 
Seizure Monitoring 
Seizure activity was assessed via continuous video EEG monitoring throughout the inpatient 
stay. Video EEG is considered one of the most important diagnostic tests for the evaluation of 
seizures. It allows a provider to visualize an event or symptom that occurs while conducting 
normal daily activities and sleep. The procedure requires hospital admission with a 3 to 5 day 
average length of stay. After admission, providers often lower or discontinue ASMs and may 
introduce stimuli in order to induce seizure activity. The patient wears an EEG transmitter and 
video cameras provide continuous behavioral observation. Both EEG and video signals are 
transmitted to a control room where the EEG is reformatted and conducted to a video monitor. 
The EEG signal and video are displayed simultaneously for on-line observation by EEG 
technologists and both are recorded on videotape. The goal of testing is to record typical seizures 





Metabolic profiling was accomplished using recently developed NoviPlex™ cards. These, 
Food and Drug Administration (FDA) approved devices produce plasma aliquot discs from a 
fingerstick. NoviPlex Technology uses advanced membrane systems to pull the plasma from 
whole blood while leaving the blood cells behind. After application, rapid air-drying stabilizes the 
sample and the dried plasma discs remain stable at room temperature until analysis is completed.  
Study personnel trained subjects to conduct fingersticks for NoviPlex card blood samples 
utilizing a single-use, contact-activated lancet. Each subject performed one fingerstick daily for 
blood collection purposes during the course of his or her hospitalization. Pediatric patients 
performed the fingerstick themselves (if able) or received assistance for a parent or guardian. 
Careful attention was paid to instruct subjects on use of sterile alcohol wipes to clean the puncture 
site before the fingerstick and correct lancet positioning in order to minimize risk of infection and 
pain. Once the lancet was deployed, blood from the single puncture site was applied to two 
separate NoviPlex cards (NoviPlex Card 1 and NoviPlex Card 2).  
As less than 1 mL of blood is required in order to form each plasma aliquot disc, one 
fingerstick produced enough blood for the separate cards. NoviPlex Card 2 served to confirm the 
metabolic profiling completed on NoviPlex Card 1 or as a back-up in the event that NoviPlex 
Card 1 was deemed defective. If the subject did not produce enough blood to collect a second 
sample, the procedure was aborted and metabolic profiling was completed only on NoviPlex Card 
1. A second fingerstick was not pursued. 
On the day of admission (NoviPlex Day 0), a non-fasting fingerstick was performed prior to 
reduction or discontinuation of ASMs to serve as a control sample. Each subsequent day of 
admission (NoviPlex Day 1-5), subjects were instructed to perform the fingerstick in the morning 
before eating breakfast. Study personnel rounded on subjects once to twice daily to ensure 
samples were collected in a fasting state. Fingersticks not performed or peformed following oral 
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intake were documented in the data collection form. Completed NoviPlex cards were each labeled 
with the subject ID, date, and NoviPlex Card day (Table 5).  
 
Table 5: NoviPlex™ Card Labeling System 
Day of Admission NoviPlex Card Labels 
Hospital Day 1 Card 1 Day 0 Card 2 Day 0 
Hospital Day 2 Card 1 Day 1 Card 2 Day 1 
Hospital Day 3 Card 1 Day 2 Card 2 Day 2 
Hospital Day 4 Card 1 Day 3 Card 2 Day 3 
Hospital Day 5 Card 1 Day 4 Card 2 Day 4 
Hospital Day 6 Card 1 Day 5 Card 2 Day 5 
 
Prior to discharge from the hospital, study personnel collected NoviPlex cards and any 
remaining fingerstick supplies. Completed NoviPlex cards were placed in a sealed envelope and 
transported to the biochemistry lab by study personnel for metabolomic profiling. Alliquot 
samples and NoviPlex cards were destroyed after analysis. This data will be used in a subsequent 





Results from the Harvard FFQ were reviewed and analyzed for total dietary intake of 
kilocalories (kcal), fat, PUFAs and SFAs per day. Independent variables for the primary outcome 
of the study included the following PUFA and SFA intakes in grams per day: total n-3, ALA, 
EPA, DHA, total n-6, LA, AA, and total SFA, Butyric (C4:0), Caproic (C6:0), Octanoic (C8:0), 
Decanoic C10:0), Dodecanoic (C12:0), Myristic (C14:0), Palmitic (C16:0) and Stearic (C18:0) 
acids. SFAs were sub-categorized into groups based on carbon chain length. In our analysis, 
Butyric (C4:0) and Caproic (C6:0) acids were classified as SCFAs, Octanoic (C8:0), Decanoic 
C10:0) and Dodecanoic (C12:0) acids as MCFAs and Myristic (C14:0), Palmitic (C16:0) and 
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Stearic (C18:0) acids as LCFAs.  Total daily intake of n-6 and n-3 FAs was also expressed as a 
ratio of n-6:n-3. 
 
Seizure Presence and Severity 
Following discharge, board-certified neurologist and epileptologist, Dr. Arun Swaminathan, 
reviewed completed EEG reports for each subject and assessed seizure presence and severity. 
Seizure presence and severity served as dependent variables of the primary and secondary 
outcomes of the study, respectively. Classification of seizure severity was accomplished by 
assigning a score to each subject based on seizure activity interpreted from the continuous video 
EEG (Table 6). A score of 0 indicated no seizure activity was captured during the stay, while a 
score of 1-4 indicated seizure presence. Single or few brief seizures with minimal impairment of 
awareness or preserved awareness received a score of 1 while single or multiple complex partial 
seizures received a 2. A 3 indicated one Tonic Clonic or one Grand Mal Seizure with a score of 4 
representing more than one Tonic Clonic or Grand Mal seizure.  
 
Table 6: Seizure Severity Score Key 
Score Seizure Severity 
0 No seizure 
1 Single or few brief seizures with minimal impairment of awareness or preserved awareness 
2 Single or multiple complex partial seizures 
3 1 Tonic Clonic or 1 Grand Mal 




Baseline and clinical data including sex, age, ethnicity, height, weight, and BMI were 




Descriptive statistics were calculated and are provided as means, standard deviations, 
medians and ranges for continuous variables, and frequencies and percentages for categorical 
variables. To determine if dietary FA intake (PUFA, SCFA, MCFA and LCFA) could impact 
presence of seizures, FA intake in subjects with documented seizure presence were compared 
with FA intake of those without using a Mann Whitney U-test. Univariate and multivariate 
logistic regression, adjusted for age, sex, BMI and total calorie intake, were leveraged to assess 
the impact of dietary FA intake on seizure presence. The confounders were chosen a priori based 
on clinical knowledge of relationships. 
Next, the relationship between dietary FA intakes and seizure severity were examined in 
subjects with documented seizure presence (seizure severity groups 1-4). Mean ranks of dietary 
PUFA, SCFA, MCFA and LCFA intake, were compared between seizure severity groups using a 
Kruskal-Wallis test. Any significant findings were corrected by using a Bonferoni post-hoc 
analysis. Univariate and multivariate linear regression were utilized to evaluate if PUFA, SCFA, 
MCFA and LCFA were predictors of seizure severity. In an effort to avoid collinearity, individual 
FAs were evaluated separately in all regression models. Given the nature of the data, univariate 
and multivariate ordinal logistic regression models for PUFA, SCFA, MCFA and LCFA intake 
were also explored to determine if dietary FA intake increased or decreased the proportional odds 
of falling at a higher seizure severity score. Assumptions of regression models were tested to 
ensure valid statistical tests. 
All tests were two-sided and a P-value < 0.05 was considered statistically significant. A 
power analysis was not calculated as the goal of this study was to collect pilot data. Statistical 






CHAPTER 3: RESULTS 
Participants 
Eighty-five subjects were successfully enrolled into the study. Three subjects were excluded 
from the final analysis for the following reasons: not completing a FFQ, leaving prior to 
completion of EEG monitoring, and a FFQ reporting a total daily intake of over 6000 calories per 
day. Therefore, a total of 82 subjects were included in the analysis (Figure 5). Subject 









Figure 5: Subject Enrollment, Exclusion and Inclusion in the Final Analysis. Informed consent was obtained 
from 85 Subjects. Three subjects were excluded for the following reasons: not completing a FFQ, leaving prior 
to completion of EEG monitoring, and a FFQ reporting a total daily intake of over 6000 calories per day, 
providing A total of 82 subjects were included in the final analysis. Of 82 subjects in the final analysis, seizure 
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Of the 82 subjects included in the analysis, 26 (31.7%) were male with 74 (90.2%) 
identifying as Caucasian, 4 (4.2%) as African American, 3 (3.1%) as Hispanic and 1 (1.0%) as 
Asian American. The cohort’s median age was 36.5 years with a BMI of 30.5 kg/m2. During 
admission, seizure presence was observed in 31 (37.8%) of subjects. The distribution of seizure 
severity scores among those with seizures include 4 (4.2%) with a score of one, 18 (22.0%) with a 
score of two, 5 (6.1%) with a score of three and 4 (4.9%) with a score of four.   
 
 
Table 7: Baseline Characteristics of 82 Subjects Included in the Final Analysis 
Categorical Demographics (n=82) n (%)   
Sex      
 Male  26 (31.7)   
 Female  56 (68.3)   
Race      
 Caucasian  74 (90.2)   
 African American  4 (4.2)   
 Hispanic  3 (3.1)   
 Asian American  1 (1.0)   
Seizure Presence      
 No  51 (62.2)   
 Yes  31 (37.8)   
Seizure Severity      
 1 4 (4.2)   
 2 18 (22.0)   
 3 5 (6.1)   
 4 4 (4.9)   
Continuous Demographics (n=82) Mean + SD Median Range 
Age (years)   38.1 + 14.0 36.5 67 
BMI (kg/m2)   31.4 + 8.6 30.5 38.2 
Dietary Intake      
 Calorie, kcals/d 2112 + 1045.4 1813.5 5412.6 
 Protein, gm/d 93.4 + 57.1 76.5 365.6 
 Carbohydrate, gm/d 253.1 + 120.0 228.0 572.4 
 Fat, gm/d 82.3 + 46.7 72.2 214.5 
 Total Omega-3, gm/d 1.8 + 1.0 1.5 5.1 
 Alpha Linolenic Acid, gm/d 1.5 + 0.8 1.3 4.4 
 Eicosapentaenoic Acid, gm/d 0.07 + 0.1 0.02 0.7 
 Docosahexaenoic Acid, gm/d 0.14 + 0.2 0.07 0.2 
 Total Omega-6, gm/d 15.5  + 8.6 13.7 45.9 
 Linoleic Acid, gm/d 14.01 + 7.7 12.7 41.0 
 Arachadonic Acid, gm/d 0.21 + 0.2 0.16 1.3 
 Omega-6:Omega-3, gm/d 8.9 + 2.2 8.8 15.1 
 Total Saturated Fatty Acid, gm/d 29.0 + 16.9 25.3 82.5 
 Short Chain Fatty Acid, gm/d  1.0 + 0.8 0.8 4.4 
 Medium Chain Fatty Acid, gm/d 3.8 + 2.6 3.2 14.1 
 Long Chain Fatty Acid, gm/d 22.7 + 13.1 19.3 64.7 
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Median dietary intakes of macronutrients in the total population consisted of 1813.5 calories, 
76.5 grams (gm) protein, 228.0 gm carbohydrate and 72.2 gm fat per day. Protein, carbohydrate 
and fat comprised approximately 15%, 50% and 35% of total daily caloric intake, respectively.  
Median PUFA intake for the cohort was 1.5 gm of n-3 with 1.32 gm ALA, 0.02 gm EPA, 0.07 
gm DHA (Figure 6) and 13.7 gm n-6 with 12.7 gm LA, 0.16 gm AA per day (Figure 7). The 
overall n-6 to n-3 ratio for the cohort was 8.8:1. Finally, median daily intakes of total SFAs was 










Figure 8: SCFA, MCFA and 
LCFA as Proportions of SFA 
Intake. SCFA comprised 3.2% 
with MCFA and LCFA 









Figure 6: ALA, DHA and EPA 
as Proportions of N-3 FA 
intake. ALA comprised 86.7% 
with EPA and DHA comprising 
1.3% and 4.7%, respectively.  
 
 
Figure 7: LA and AA as 
Proportions of the N-6 FA 
intake. LA comprised 92.7% 













Dietary FA Intake and Seizure Presence 
 
Table 8: Baseline Characteristics of Seizure Absence vs. Seizure Presence Groups 
  Seizure Absence  
(n=51) 
Seizure Presence  
(n=31) 
 
Categorical Demographics n (%) pa 
     
Sex    0.04* 
 Male 12 (23.5) 14 (45.2)  
 Female 31 (60.8) 17 (54.8)  
Ethnicity    0.36 
 Caucasian 48 (92.3) 26 (83.9)  
 African American 2 (3.9) 2 (6.5)  
 Hispanic 1 (1.9) 2 (6.5)  
 Asian American 0 (0.0) 1 (3.2)  
Continuous Demographics  Median pb 
Age (years)  36 40 0.61 
BMI (kg/m2)  30.67 30.24 0.56 
Calorie Intake (kcals/d)  1760.5 1954.5 0.18 
aChi Square Test to compare seizure absence and seizure presence groups 
bMann-Whitney U Test to compare seizure absence and seizure presence groups 
*Statistically significant p-value <0.05 
 
 
A Mann-Whitney U test comparing median dietary FA intakes between seizure presence 
groups (seizure absence vs seizure presence [Table 8]) showed marginally significant differences 
in median SCFAs (0.65 gm vs 1.01 gm for no vs. yes seizure presence, p = 0.07) and MCFAs 
(2.92 gm vs 3.82 gm for no vs. yes seizure presence, p = 0.07) (Table 9). No statistically 




Table 9: Differenced in Median Dietary FA Intakes Between Seizure Absence and Seizure Presence 
Groups (n=82) 
Fatty Acid 





Total Fat, gm/d 71.8 76.0 0.3 
Total N-3, gm/d 1.4 1.6 0.3 
ALA, gm/d 1.2 1.4 0.5 
EPA, gm/d 0.02 0.02 0.3 
DHA, gm/d  0.07 0.08 0.28 
Total N-6, gm/d 13.7 13.2 0.4 
LA, gm/d 12.7 12.4 0.4 
AA, gm/d 0.2 0.2 0.5 
N-6:N-3, gm/d 8.8 8.9 0.9 
Total SFA, gm/d 22.1 26.8 0.2 
SCFA, gm/d 0.65 1.01 0.07+ 
MCFA, gm/d 2.92 3.83 0.07+ 
LCFA, gm/d 17.9 20.01 0.2 
aMann-Whitney U Test to compare seizure absence and seizure presence groups 
+




Figure 9: Median Dietary Total, N-3, N-6, N-6:N-3 Ratio and SFA Intakes in Seizure Absence and Seizure 
Presence Groups. FA intake (gm/d) represented above corresponding seizure absence and seizure presence 


































Seizure Absence Seizure Presence
44 
 
 Logistic Regression modeling assumptions were verified and goodness of fit was confirmed 
using Hosmer Lemeshow (p = 0.09). Results of both univariate and multivariate models were 
unable to show dietary FA intake increased or decreased risk of seizure presence (Table 10).   
         
Table 10: Results of Univariate and Multivariate Logistic Regression between FA Intake and 
Seizure Presence 
Fatty Acid Intake (gm/d) 
Univariate Multivariate 
OR 95% CI p
a
 OR 95% CI p
b
 
Total Fat 1.0 1.0, 1.0 0.26 1.0 1.0, 1.02 0.42 
Total n-3 1.2 0.8, 1.8 0.45 0.61 0.2, 1.6 0.33 
ALA  1.2 0.7, 2.0 0.54 0.43 0.1, 1.6 0.22 
EPA  6.4 0.2, 199.4 0.29 2.77 0.1, 117.4 0.59 
DHA  1.7 0.2, 14.3 0.63 0.58 0.5, 7.3 0.67 
Total n-6  1.0 1.0, 1.1 0.35 0.96 0.8, 1.1 0.61 
LA  1.0 1.0, 1.1 0.37 -0.04 0.8, 1.1 0.62 
AA  2.5 0.3, 19.2 0.38 0.46 0.02, 12.1 0.64 
N-6:N-3 1.0 0.8, 1.2 0.83 0.99 0.8, 1.2 0.92 
Total SFA  1.0 1.0, 1.0 0.13 1.02 1.0, 1.1 0.54 
SCFA  1.5 0.9, 2.7 0.15 1.27 0.6, 2.7 0.53 
MCFA 1.2 1.0, 1.4 0.1 1.12 0.9, 1.5 0.41 
LCFA  1.0 1.0, 1.1 0.17 1.02 0.9, 1.1 0.68 
a
Univariate Logistic Regression of FA intake and  seizure presence risk 
b
Multivariate Logistic Regression of FA intake and seizure presence risk, adjusted for age, sex, BMI 
and  total calorie intake  




Dietary FA Intake and Seizure Presence 
Results of the Kruskal-Wallis test showed there were no significant differences in FA intake 
between seizure severity groups (Table 11, Figure 10). A post-hoc analysis was not performed 
due to lack of significant results.  
 
Table 11: Differences in Median Dietary FA Intakes among Seizure Severity Groups 
Fatty Acid Intake (gm/d) 
Seizure Severity Score Groups 
pa 
1 (n=4) 2 (n=18) 3 (n=5) 4 (n=4) 
Total N-3 1.11 1.61 1.59 1.61 0.6 
ALA 0.99 1.39 1.34 1.3 0.68 
EPA 0.00 0.03 0.03 0.02 0.3 
DHA 0.04 0.09 0.15 0.1 0.51 
Total N-6 9.8 13.73  19.15 16.15 0.43 
LA 8.61 12.62 18.45 14.56 0.43 
AA 0.16 0.16 0.22 0.15 0.84 
N-6:N-3 8.36 8.87 8.34 10.08 0.52 
Total SFA 23.79 26.32 27.73 26.44 0.9 
SCFA 0.95 1.03 1.08 0.58 0.9 
MCFA 3.64 4.11 4.08 2.74 0.88 
LCFA 18.98 19.57 23.82 22.21 0.89 
aKruskal-Wallis test to compare across all seizure severity categories 
Group 1: Single or few brief seizures with minimal impairment of awareness or preserved awareness; Group 2: 
Single or multiple complex partial seizures; Group 3: 1 Tonic Clonic or 1 Grand Mal seizure; Group 4: >1 Tonic 







Figure 10: Median Daily FA Intake (gm/d) by Seizure Severity Score Group. Group 1: Single or few brief seizures 
with minimal impairment of awareness or preserved awareness; Group 2: Single or multiple complex partial 
seizures; Group 3: 1 Tonic Clonic or 1 Grand Mal seizure; Group 4: >1 Tonic Clonic or >1 Grand Mal seizure. 
Dotted line represents the trend toward significance of the inverse linear relationship between MCFA intake and 
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Tests of assumptions for linear regression showed that this method was an appropriate fit for 
modeling the data (Figures 11, 12). No significant associations between dietary FA intake and 
seizure severity scores were observed using univariate linear regression (Table 12). After 
adjusting for the relevant confounders of age, sex, BMI and total calorie intake, results remain 
insignificant. However, a trend toward significance was seen with the relationship between 
MCFA intake and seizure severity (p = 0.16) (Table 12). Univariate and multivariate ordinal 
logistic regression models violated statistical assumptions. Therefore, data were unable to provide 
insights on the impact of dietary FAs on the proportional odds of falling into a seizure severity 
group.  
 
Table 12: Results of Univariate and Multivariate Linear Regression between FA Intake 
(gm/d) and Seizure Severity Score (n=31) 







Total N-3 0.21 0.00 0.91 -0.23 0.55 
ALA 0.00 0.00 0.98 -0.38 0.41 
EPA -0.02 -0.02 0.9 0.64 0.58 
DHA 0.13 0.74 0.49 -0.2 0.83 
Total N-6 0.02 0.09 0.91 0.03 0.52 
LA 0.01 0.08 0.68 0.04 0.4 
AA 0.1 0.01 0.6 -1.12 0.38 
N-6:N-3 -0.04 -0.13 0.83 0.1 0.22 
Total SFA 0.19 0.07 0.31 -0.02 0.35 
SCFA -0.04 -0.00 0.81 -0.29 0.2 
MCFA -0.17 -0.16 0.36 -0.11 0.16§ 
LCFA -0.14 -0.04 0.45 -0.02 0.5 
a
Univariate Linear Regression of FA intake predicting seizure severity  
b
Multivariate Linear Regression of FA intake predicting seizure severity, adjusted for age, sex, BMI 
and  total calorie intake 



















Figure 11: Normal P-P Plot (observed vs. expected cumulative distribution 
of the standardized residual) of multivariate linear regression for MCFA 
 
 
Figure 12: Homoscedasticity Represented by a Scatterplot of Predicted vs. Residual Values from 
Multivariate Linear Regression for MCFA 
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CHAPTER 4: DISCUSSION 
Key Results 
Published research suggests increased dietary intake or supplementation of n-3 FA, SCFA 
and/or MCFA may elicit anticonvulsant properties through one or more of the previously 
described theorized mechanisms. Further, data indicate increased LCFA intake, n-6 intake and/or 
a high n-6:n-3 ratio could result in an overexpression of cytokines, leading to a decrease in 
seizure threshold and an increase in spontaneous seizure frequency.  
 To the best of our knowledge, this is the first study to examine the impact of dietary PUFA 
and SFA intakes on seizure presence and severity in a cohort of subjects admitted to an EMU. In 
this analysis of a prospective cohort, we show increased dietary MCFA may be associated with 
decreased seizure severity in individuals with epilepsy. Additionally, a FFQ provides unique 
insights into the long-term effects of dietary intake on seizure outcomes.  
 
Dietary Intake of the Cohort 
In our final analysis, the cohort consumed adequate median intakes of calories and protein, 
equating 20.7 kcal/kg and 0.9 g/kg, respectfully with a median cohort BMI of 30.5 kg/m2. 
Macronutrient distributions indicate dietary intake is 
representative of a typical Western diet pattern. Here, 
fat provided approximately 35% of calories with 50% 
from carbohydrates (Figure 13). In comparison, 
KDTs consistently provide greater than 50% of total 
calories per day from fat with less than 20% from 
carbohydrate. Therefore, we can assume that results 
in this study are reflective of the influence of 
individual FAs rather than a KDT. Although KBs 
 
Figure 13: Carbohydrate, Protein and Fat as 
Proportions of the Total Median Daily 
Calorie Intake. Carbohydrates comprised 
approximately 50% with protein and fat 








may have been produced from MCFA consumption, we do not anticipate high circulating levels 
in the plasma. 
Daily median total n-3 intake of our sample was 1.5 gm/d, with 1.3 gm/d (87%) of that total 
as ALA. Although a low n-3 intake is common in a Western diet pattern, cohort median intakes 
of ALA were above the AI as set by the IOM for adult females between the ages of 19 and 50. 
(Figure 14). Median intakes of EPA and DHA in this study were 0.02 and 0.07 gm/d, respectively 
with a combined intake of 0.09 gm/d. While we cannot account for the endogenous production of 
EPA and DHA intake from ALA, we can assume conversion is very low (0-4%) and likely did 
not contribute largely to overall availability in the body. Current recommendations, as proposed 
by the World Health Organization (WHO) [250], for combined intake of EPA and DHA are 0.25-
0.5 gm/day in healthy individuals and is thought to be much higher in those with chronic 
inflammatory conditions. Therefore, although these individuals met the IOM recommendations 
for n-3, they only consumed 36% of the lower end of threshold for these FAs that are vital in the 
brain. 
Total dietary n-6 intake of our cohort was 13.7 gm/d with 12.7 gm (93%) of total intake 
consumed as LA and 0.16 gm/d as AA. LA intake met the IOM AI recommendation of 12 gm/d 
for women between the ages of 19 and 50 (Figure 14). Median total intake of n-6 and n-3 FAs 
resulted in an n-6:n-3 ratio of 8.8:1. While the n-6:n-3 ratio of our cohort was above the 
recommendation of 5:1, it fell far below the average ratio of a human consuming a Western diet 
which has been estimated at approximately 16:1. Generally, the higher ratios seen in this diet 
pattern are due to high concentrations of n-6 FAs in meats, eggs and processed foods made with 







Although SCFAs, MCFAs and LCFAs are considerably different in both structure and 
function, they are often thought of a single SFA group. As previously discussed, there are 
currently no governmental recommendations for daily SFA intake as they are not seen as essential 
to the prevention of chronic diseases. However, recent findings, which show specific SFAs are 
beneficial in multiple disease processes from obesity and diabetes to neurological diseases, may 
require recommendations to be formed. With a median total fat intake of 72.2 gm/d, our cohort 
consumed 25.29 gm/d, or 35%, of fat calories as SFA. Here, intake was considerably higher than 





Figure 14: Recommended vs Cohort Dietary PUFA Intakes, gm/d. Recommendations for n-6 (LA) and n-3 
(ALA) based on AIs for adult females between 19 and 50 as proposed by the IOM. Recommendations for n-
6:n-3 of 5:1 based on the recommendation by Simopoulas  et al. [65]. Recommendations for combined EPA 
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Dietary Intake of FAs across Seizure Absence and Seizure Presence Groups 
When comparing dietary FA intake in subjects with seizure absence against those with 
seizure presence, no statistically significant differences were seen in any PUFA or LCFA intake 
and seizure activity groups. However, there was a marginally significant difference in dietary 
intakes of SCFA and MCFA between seizure groups (both p = 0.07), with higher intakes of 
SCFA and MCFA in the seizure presence group. Due to the ability of SCFAs to inhibit HDACs 
and decrease inflammation along with MCFAs ability to inhibit AMPA receptors, we may 
suspect increased dietary intake of both SFAs to increase seizure thresholds and reduce seizure 
occurrence [123, 144, 175, 176, 182, 210]. Yet, contrary to the aforementioned literature, data in 
this analysis may be initially interpreted as individuals consuming higher amounts of SCFAs and 
MCFAs experience seizures.  
Upon further evaluation, however, the marginally significant difference in dietary SCFA and 
MCFA intakes are likely more reflective of the overall variation in dietary intake between seizure 
presence groups rather than an effect of the FAs themselves. While no statistically significant 
differences in median calorie and SFA intake are seen among seizure absence or presence groups 
(p = 0.18 and p = 0.16, respectfully), a clinically significant difference was observed. Median 
calorie intake was 194.5 kilocalories, or a substantial 10% higher in the seizure presence group. 
Median intake of SFA was a total of 4.7 gm higher in the seizure presence group with SCFA and 
MCFA contributing 0.36 gm/d and 0.91 gm/d to that total, respectfully. Although the median 
intake of total fat was only 4.2 gm/d higher in the seizure presence group, median intake of SFA 
was 4.7 gm/d higher, indicating a disproportionally high amount of the increased fat consumed 
included SFA (Figure 9). Interestingly, although median calorie intake was 10% higher in the 
seizure presence group, there was extremely little variation in n-3 and n-6 FAs intakes. In fact, 




Dietary FA Intake and Risk of Seizure Presence or Seizure Absence 
In this analysis, univariate and multivariate logistic regression models were unable to show 
dietary FA intake increased or decreased risk of seizure activity in this cohort. Small variation in 
PUFA intake along with a disproportionally high SFA intake in the seizure presence group likely 
contributed to the null results of the logistic regression model. However, results were likely also 
influenced by the amounts of FAs consumed in the seizure presence group.  
 Previous research suggests appropriate n-3 dose and adequate duration of administration are 
integral to observe the therapeutic effect of the FA in people with epilepsy. While consistent n-3 
intakes of greater than 1.1 to 3.2 gm/d have been proposed, an optimal dose is currently unknown 
and clinical trials have produced inconsistent results [216]. Recently, data have indicated that 
EPA and DHA may be responsible for many of the beneficial effects seen from n-3 FAs in 
neurological diseases. EPA and DHA serve as precursors to SPM, which are responsible for the 
endogenous mediation of inflammation. Decreased concentrations of plasma SPM have been 
found in individuals with neurological disease compared to healthy controls, possibly implying 
that these individuals utilize more SPM in an attempt to decrease the negative effects of 
neuroinflammation [173]. DHA has also specifically been shown to reduce neuronal 
hyperexcitability by suppressing conductance of currents in neuronal cells. As previously 
discussed, up to 60% of lipids incorporated in neural membranes consist of DHA. However, 
decreased consumption of n-3 PUFAs results in a partial replacement of DHA by AA in the 
neuronal cell membrane, likely eliminating the potential anticonvulsant mechanism [75]. 
Therefore, adequate substrate must be available to saturate the neural cell membrane and 
contribute to the pool of SPM available to decrease neuroinflammation. Many studies indicate a 
sustained intake of a least one gm of DHA per day is needed to impact neurological outcomes. 
Therefore, although median n-3 intake is above the minimum threshold suggested by Auvin et al., 
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perhaps the proportion of that intake from DHA or the conversion of ALA to DHA was too low 
to stimulate a protective effect [216].  
While marginally significant differences of SCFAs and MCFAs in seizure activity groups 
were expected to be due to variation in intake, logistic regression modeling appears to confirm 
this assumption. In the multivariate model, total SFA, SCFA, MCFA and LCFA intake was 
unable to predict seizure activity, as evidenced by each 95% confidence interval for odds ratios 
(OR) containing the null (one). The 2019 publication by Citraro et al., notes unpublished data 
have indicated that a NaB dose of 30 mg/kg only minimally modifies seizure activity. Median 
SCFA intake of the seizure presence group was 1.01 gm/day or approximately 11.5 mg/kg [240]. 
Although we cannot account for endogenous production of SCFAs in the intestine, we may 
suspect that intake is not high enough to drastically impact outcomes. 
Direct inhibition of AMPA-receptor activity has been well established as an effective 
therapeutic mechanism in focal seizures and generalized tonic–clonic seizures. In fact the 
antiepileptic drug perampanel acts directly on AMPA receptors but at a different site from MCFA  
[251]. Mean serum concentrations of decanoic acid (C10:0) in patients on a MCTKD have been 
reported as 157 µmol/L. In the work by Chang et al., data indicate that 100 µmol/L decanoic acid 
(C10:0) results in a 3-fold increase in the inhibition of the AMPA receptor [144]. The report by 
St-Pierre et al. found provision of MCFA with a carbohydrate-rich diet could dose-dependently 
increase corresponding plasma levels after ingestion [111]. Here, providing 20 mL, or 
approximately 18.5 gm, of MCFA produced an 80-90 µmol/L increase after a single dose. 
Median intake of MCFAs in the seizure presence group was 3.8 gm/d, which likely corresponds 
to a relatively low serum concentration. While this intake may be beneficial in inhibiting AMPA 
receptors, there is currently a paucity of data to indicate a MCFA dose needed in order to 
influence clinical outcomes. 
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N-3 PUFAs, DHA, SCFA and MCFA are all associated with anti-seizure properties. 
Consequently, a plausible explanation for our inability to observe the ability of FA intake to 
predict seizure activity is the simple fact that dietary intake wasn’t high enough to elicit anti-
seizure attributes.  
 
Dietary Intake of the FAs across Seizure Severity Groups 
In subjects with seizure presence, no statistically significant differences were seen in FA 
intake among seizure severity groups. However, clinical differences may provide insights on the 
relationships between dietary FA intake and seizure severity.  
The median n-6:n-3 ratio in subjects experiencing a seizure severity score of 4 was 10.1:1, 
which was higher than those receiving a score of 1 (8.36:1), 2 (8.87:1) or 3 (8.34:1). The n:6-n:3 
ratio is of particular importance in the brain due to the competitive absorption of the two essential 
FAs. As previously described, small changes in dietary intake of FAs can alter brain lipid 
composition. Even a small increase in n-6 consumption may result in higher levels of brain AA 
and lower levels of DHA. Further, the higher n-6 intake and competitive absorption may negate 
the potential for beneficial effects to be seen by n-3 FAs and potentially increase dosage 
recommendations even more. This may be one explanation as to why seizure severity group 4 did 
not see beneficial effects of consuming higher amounts of n-3 FA, EPA and DHA (1.61, 0.02, 0.1 
gm/d, respectively) as compared to group 1 (1.11, 0.00, 0.04 gm/d, respectively).  
Another interesting clinical difference was the intake of n-6 PUFAs and LCFAs across 
seizure severity groups. Median intakes of n-6 and LCFAs were higher in seizure severity group 4 
(SCFA: 16.15 gm/d; LCFA: 22.21 gm/d) than in group 1 (SCFA: 9.8 gm/d; LCFA: 18.98 gm/d) 
(Figure 15). High intakes of these FAs are highly prevalent in a standard Western diet and both 
have been shown to increase neuroinflammation by triggering the release of cytokines in the 
brain. As increased cytokine levels lead to a decrease in seizure threshold and an increase in 
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spontaneous seizure frequency [159], it is entirely possible that increased n-6 and LCFAs 
perpetuated seizure activity and resulted in increased seizure severity in the group.  
  
 
In contrast, median intakes of SCFAs and MCFAs were lowest in subjects experiencing the 
most severe seizures (seizure severity group 4). Median intakes of SCFAs in seizure severity 
groups 1, 2, 3 and 4 were 0.95, 1.03, 1.08 and 0.58 gm/d, respectively, while median MCFAs in 
groups 1-4 were 3.64, 4.11, 4.08, and 2.74 gm/d, respectively. From these results, we may 
hypothesize that SCFA or MCFA above a certain threshold may inhibit the progression of 
multiple, severe seizures. Higher intakes may be especially significant in this cohort, where 
ASMs have been reduced or stopped for continuous EEG assessment of seizure activity during 
admission.  
 
Figure 15: Median Daily FA Intake (gm/d) of Seizure Severity Groups 1 and 4. Group 1: Single or few brief 
seizures with minimal impairment of awareness or preserved awareness; Group 4: >1 Tonic Clonic or >1 Grand 
Mal seizure. Dotted line represents the trend toward significance of the inverse linear relationship between MCFA 
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Together, these clinical observations suggest a potential relationship between FA intake and 
seizure severity. Even with dietary intakes far below what may be considered a therapeutic dose, 
the influence of FA intake appeared possible in subjects with seizure presence. 
 
Dietary FA Intake Predicting Seizure Severity 
When assessing the ability of FAs to predict seizure severity, we observed a trend toward 
significance in the ability of dietary MCFA intake to predict seizure severity in the multivariate 
linear regression model (β = -0.11, p = 0.16). In previous discussion, we note MCFA dose-
dependently increased in the serum of subjects on a carbohydrate-rich diet and AMPA receptors 
were inhibited 3-fold in mice with a serum level greater than 100 µmol/L [111, 144]. Here, results 
may reflect the impact of increased dietary MCFA intake on AMPA receptor inhibition and the 
ability to decrease seizure severity.  
In this analysis, no significant results were identified in the remaining PUFAs or SFAs in 
univariate or multivariate modeling. However, the direction of these FAs in the multivariate 
regression provide interesting insights into relationships with seizure severity. An inverse linear 
relationship was observed in total n-3, ALA, DHA, AA, total SFA, SCFA and LCFA. The FAs 
EPA, total n-6, LA and the n-6:n-3 ratio resulted in a positive linear relationship. Once again, the 
majority of the FAs follow the trends seen in research on FA intake and seizure activity. We 
anticipate a cohort with increased variability of FA intake would further elucidate the strength 
and direction of these relationships.  
 
PUFAs, SFAs and KDTs as Epilepsy Treatment 
In the fasting state, plasma FAs increase almost entirely from hydrolysis of triglycerides, 
while FAs are metabolized for energy in the absence of carbohydrates in a KDT. Historically, the 
production and metabolism of KBs has been considered fundamental to the anti-seizure effects of 
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a KDT or starvation. However, more recent research questions this position, prompting 
investigations into alternative theories.  
Both KDTs and individual FAs have been associated with potential mechanisms of action to 
inhibit seizure activity or increase seizure thresholds (Table 13). Namely, the ability to alter 
neurotransmitters, activate PPARγ, mediate neuroinflammation and inhibit HDACs [252]. While 
all four KDTs have been shown to be effective, the adverse effects, low retention rates and 
unknown impact on long-term health outcomes often prevent their use as first-line therapy. 
Identification of anti-seizure mechanisms of action in KDTs could allow for diet liberalization, 
increased quality of life and a true treatment for epileptogenesis. Therefore, it will be important to 
distinguish if the favorable effects of a KDT are truly a function of KB production, increased 
accumulation and metabolism of FAs, or perhaps both.  
 
Table 13: Common Theorized Mechanisms of Action between KDTs, N-3s, SCFAs and MCFAs 
Theorized Mechanism of Action 
Dietary Component Catalyst 
KDT N-3  SCFA MCFA 
Alter Neurotransmitters X X X X 
Activate PPARγ X X X X 
Inhibit HDAC X  X  
Mediate Neuroinflammation X X X  
 
There is a well-established fact that there are both responders and non-responders to KDT. 
Responders are often classified as subjects with a greater than 50% improvement in seizure 
activity from baseline within a specified time period. With the exception of specific metabolic 
disorders, prediction of the response to therapy is currently unknown [253, 254]. One potential 
explanation for the unpredictable response could be that patient’s circulating FA levels aren’t 
high enough to benefit from therapy.   
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Although the brain represents only 2% of body weight, it consumes 20-23% of whole-body 
energy in healthy individuals [252]. However, we may suspect that brain energy requirements of 
an individual with epilepsy may be much higher due to increased activity. Previous research by 
Wang et al. reported lower levels of FAs after seizures, indicating their increased consumption 
during seizure occurrence [44]. As increased consumption likely results in decreased levels of 
FAs in the brain, the ability of a KDT to increase serum levels of PUFAs and SFAs may be 
associated with its anti-seizure effects. We may speculate lower levels of FAs, specifically in the 
brain, may decrease many of the aforementioned theorized mechanisms of action [44]. Inadequate 
circulating levels within a specified timeframe could be due to the patient’s baseline dietary 
pattern, increased brain consumption due to seizure activity or an inability to follow a KDT for a 
prolonged period of time. As seen in the research of n-3 PUFA supplementation in pre-clinical 
and clinical epilepsy research, length of supplementation is often considered paramount to ensure 
efficacy [216, 226, 228, 233, 235]. Although data often suggest a minimum length of 
supplementation of at least three months for n-3 and MCT, many studies evaluating the efficacy 
of KDTs begin assessing for a decrease in seizure activity at the one to three month mark [11, 13, 
14, 26, 255, 256]. Assessment at these early intervals may not allow enough time to increase the 
concentration of FAs in the brain. Consequently, some patients may be labeled as a “non-
responder” before the possibility of experiencing therapeutic benefit.  
Another cause for variable response to KDT could be that specific anti-seizure mechanisms 
of action are more proficient among particular seizure types and epilepsy etiologies. If so, the 
anti-seizure mechanism provoked by the FA content of a KDT may or may not be beneficial in 
the patient. Specific FAs are more prevalent in some KDTs than others. For example, a cKD is 
often characterized by high intakes of LCFAs due to its reliance on butter and cream as major fat 
sources. However, both of these foods also contain a considerable amount of SCFAs. In fact, 
butter supplies 3-4% of its fat content as butyric acid which may prevent seizure activity by 
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inhibiting HDACs or decreasing intestinal inflammation. Alternatively, the MCTKD provides 30-
60% of total energy intake from MCFAs, which has specifically been proven to inhibit AMPA 
receptors. We must also consider the possibility that a subset of seizures are directly inhibited by 
metabolism of KBs. In this case, the presence of KBs from any KDT may be beneficial to the 
patient and necessary for treatment.  
Data presented in this study suggests dietary PUFA and SFA intake may have the potential to 
influence seizure activity independent of KB production and substantiates the need for further 
research in this area. Assessing the impact of adequate DHA, SCFA and/or MCFA provision over 
a prolonged period of time will be necessary to achieve a better understanding of the anti-seizure 
properties of FAs. Furthermore, analysis of the metabolic signature of seizures via comprehensive 
metabolic profiling will be an important step in elucidating how dietary intake can impact seizure 
outcomes. Identifying the metabolic signature of seizures could allow clinicians to treat epilepsy 
through precision nutrition by providing FAs with theorized mechanisms of action to reverse the 
metabolic derangement resulting in seizure activity. We posit the provision of targeted nutrition 
interventions will increase dietary therapy retention with less restrictive requirements, allowing 
adequate time for FA accumulation in order to produce anti-seizure effects. We also anticipate 
improved “responder” rates with dietary treatments prescribed based on theorized mechanisms of 
action and the metabolic signature of the seizure.   
 
Study Strengths and Limitations 
The primary strength of this study was the use of the Harvard FFQ to evaluate the impact of 
FA intake on seizure activity in the absence of ketosis. Furthermore, this study is the first to 
establish baseline PUFA and SFA intakes in a cohort of subjects with epilepsy. Another major 
strength of this study was the use of video EEG monitoring to assess seizure presence and activity 
rather than subjective reporting.  
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Limitations of this study have been recognized. We had a limited sample size of subjects 
experiencing seizures (n = 31) with an unequal distribution across seizure severity score groups. 
The single-site study was completed at a Midwestern hospital with a largely adult, female and 
Caucasian cohort. The lack of geographic and racial diversity in the study population likely 
decreased diet variability among participants. Although epilepsy was suspected in all individuals 
admitted to the EMU, the diagnosis may have been ruled out during admission after continuous 
EEG monitoring. Therefore, it must be taken into account that some individuals in the seizure 







Epilepsy continues to affect millions of individuals around the world every day. Although 
medical treatments may improve seizure symptoms, epileptogenesis is not inhibited and many 
patients do not achieve adequate seizure control. Specific dietary FAs have potential anti-seizure 
properties that warrant further exploration as epilepsy treatment. A minimally invasive, targeted 
dietary treatment could decrease the devastating side effects of epilepsy, reduce the staggering 
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